Biomea Fusion
$1.9100
67
-$0.03-1.29% Thursday 20:00
-$0.01-0.52%Thursday 23:40After hours
Statistics
Day High
1.91
Day Low
1.905
52W High
2.99
52W Low
0.872
Volume
5,789
Avg. Volume
-
Mkt Cap
138.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
3NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.94
-0.67
-0.39
-0.12
Expected EPS
-0.225808
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-61.8MNet Income
Analyst Ratings
9.33Average Price Target
The highest estimate is 12.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow BMEA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
Editas Medicine
EDIT
Mkt Cap485.31M
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Beam Therapeutics
BEAM
Mkt Cap3.03B
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
About
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Show more...
CEO
Michael J. Hitchcock
Employees
37
Country
United States
ISIN
US09077A1060
Listings
0 Comments
Share your thoughts
FAQ
What is Biomea Fusion stock price today?▼
The current price of BMEA is $1.91 USD — it has decreased by -1.29% in the past 24 hours. Watch Biomea Fusion stock price performance more closely on the chart.
What is Biomea Fusion stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Biomea Fusion stocks are traded under the ticker BMEA.
Is Biomea Fusion stock price growing?▼
BMEA stock has risen by +10.4% compared to the previous week, the month change is a +55.28% rise, over the last year Biomea Fusion has showed a +4.37% increase.
What is Biomea Fusion market cap?▼
Today Biomea Fusion has the market capitalization of 138.44M
When is the next Biomea Fusion earnings date?▼
Biomea Fusion is going to release the next earnings report on November 03, 2026.
What were Biomea Fusion earnings last quarter?▼
BMEA earnings for the last quarter are -0.12 USD per share, whereas the estimation was -0.22 USD resulting in a +46.3% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomea Fusion revenue for the last year?▼
Biomea Fusion revenue for the last year amounts to 0 USD.
What is Biomea Fusion net income for the last year?▼
BMEA net income for the last year is -61.8M USD.
How many employees does Biomea Fusion have?▼
As of September 04, 2026, the company has 37 employees.
In which sector is Biomea Fusion located?▼
Biomea Fusion operates in the Health & Wellness sector.
When did Biomea Fusion complete a stock split?▼
Biomea Fusion has not had any recent stock splits.
Where is Biomea Fusion headquartered?▼
Biomea Fusion is headquartered in SAN CARLOS, United States.